Asia Pacific Smoking Cessation Aids Market

Market Introduction

Smoking cessation lowers the risk of cancer and other serious health problems. Some products contain nicotine as an active ingredient and others do not. Counseling, behavior therapy, medicines, and nicotine-containing products, such as nicotine patches, gum, lozenges, inhalers, and nasal sprays, may be used to help a person quit smoking. They are regulated through the FDA’s Center for Drug Evaluation and Research, which ensures that the products are safe and effective and that their benefits outweigh any known associated risks.

Market Overview and Dynamics

The Asia Pacific smoking cessation aids market is expected to reach US$ 14,753.04 million by 2028 from US$ 5,015.08 million in 2021; it is estimated to grow at a CAGR of 16.7% from 2021 to 2028. Key factors that are driving the growth of this market are increasing number of campaigns to reduce smoking and tobacco dependence and introduction of new smoking cessation aids across world. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.

The huge patient population in developing countries of Asia Pacific is generating demand for new products and therapies for smoking cessation. In addition, Southeast Asian countries has one of the highest smoking populations in the world. The population can lead to the high incidence of chronic diseases in Asia Pacific, which is a key factor increasing the number of clinical trials in Asia. Thus, the introduction of new smoking cessation products in terms of therapeutic and medical device aids in the emerging economies is likely to provide significant growth opportunities to players involved in the global smoking cessation aids market in coming years. The number of clinical trials conducted in Asia Pacific is more than those in the US or Europe owing to low operational costs, large patient recruitment potential, contract research organizations growth, favourable regulatory environment, and better clinical trials capacity and quality. The substance and tobacco abuse treatment industry are getting competitive every consecutive year with the introduction of new and innovative therapies by the market players for smoking cessation aids. In addition, medical devices such as nicotine-free e-cigarettes and vapes are being launched by market players at local and regional levels. Thus, the consistent launch of new and innovative smoking cessation aids would become a prevalent trend in the smoking cessation aids market in the coming years.

Asia Pacific countries are expecting to witness a huge challenge due to the outbreak of COVID-19. Restrictive measures such as central lockdown and trade limitations have been taken to control the spread of COVID-19. The world health organization (WHO) have been evaluating new research constantly, and it states that there is a positive relation between tobacco use and nicotine use, helping COVID-19 patients to get well. For increasing risk for COVID-19, smoking is the major cause of underlying health conditions. However, there is currently insufficient information to confirm any link between tobacco or nicotine in the prevention or treatment of COVID-19. Hence, the impact of the COVID-19 pandemic on smoking cessation aids market is low in the Asia Pacific region.

Key Market Segments

Based on product, the Asia Pacific smoking cessation aids market is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and others. In 2021, the electronic cigarettes segment is likely to hold the largest share of the market and is expected to grow at the fastest rate in the coming years.

Based on end user, the Asia Pacific smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other end users. The retail pharmacies segment is likely to hold the largest share of the market in 2021, whereas the online channel segment is anticipated to register the highest CAGR of the market during the forecast period.

Major Sources and Companies Listed

A few of the primary and secondary sources associated with this report on the Asia Pacific smoking cessation aids market are the India Brand Equity Foundation (IBEF), National Health Service (NHS) and World Health Organization (WHO).

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of Asia Pacific smoking cessation aids market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Asia Pacific smoking cessation aids market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific smoking cessation aids market.

ASIA PACIFIC SMOKING CESSATION AIDS MARKET SEGMENTATION

By Product

• Nicotine Replacement Therapy
• Drugs
• Electronic Cigarettes
• Others

By End User

• Hospital Pharmacies
• Online Channel
• Retail Pharmacies
• Other End Users

By Country

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Company Profiles

• Pfizer Inc.
• GlaxoSmithKline plc.
• Dr. Reddy's Laboratories
• Johnson and Johnson Services, Inc.
• Cipla Inc.
• Perrigo Company plc
• Bausch Health Companies Inc.
• Glenmark

Asia Pacific Smoking Cessation Aids Market Strategic Insights

Asia Pacific Smoking Cessation Aids Market Segmentation Analysis

Asia Pacific Smoking Cessation Aids Market Report Highlights

Asia Pacific Smoking Cessation Aids Report Scope

Asia Pacific Smoking Cessation Aids Market Country and Regional Insights